CN Patent

CN105566302B — 二氢吲哚酮化合物及其盐的结晶

Assigned to Qilu Pharmaceutical Co Ltd · Expires 2018-08-14 · 8y expired

What this patent protects

本发明属于医药化工技术领域，提供了一种二氢吲哚酮化合物及其盐的结晶，具体提供了一种N‑（5‑（（Z）‑(5‑氟‑2‑羰基吲哚‑3‑亚)甲基）‑2，4‑二甲基‑1氢‑吡咯‑3‑基）‑3‑（4‑甲基哌嗪‑1‑基）丙酰胺化合物、及其特定盐的结晶形式，并证明在pH6.8的磷酸盐缓冲液中具有更好的溶解度，有利于体内吸收；且具有更好的稳定性，有利于包装和贮存。

USPTO Abstract

本发明属于医药化工技术领域，提供了一种二氢吲哚酮化合物及其盐的结晶，具体提供了一种N‑（5‑（（Z）‑(5‑氟‑2‑羰基吲哚‑3‑亚)甲基）‑2，4‑二甲基‑1氢‑吡咯‑3‑基）‑3‑（4‑甲基哌嗪‑1‑基）丙酰胺化合物、及其特定盐的结晶形式，并证明在pH6.8的磷酸盐缓冲液中具有更好的溶解度，有利于体内吸收；且具有更好的稳定性，有利于包装和贮存。

Drugs covered by this patent

Patent Metadata

Patent number
CN105566302B
Jurisdiction
CN
Classification
—
Expires
2018-08-14
Drug substance claim
No
Drug product claim
No
Assignee
Qilu Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.